ADVERTISEMENT

Afinitor Boosts Effectiveness of Hormonal Therapy

Adding Afinitor, an mTOR inhibitor, to tamoxifen helped women with metastatic breast cancer live about four months longer without their disease getting worse, according to a study presented Thursday at SABCS.

BY MELISSA WEBER
PUBLISHED THURSDAY, DECEMBER 9, 2010
Talk about this article with other patients, caregivers, and advocates in the Breast CURE discussion group.
Adding Afinitor (everolimus) to tamoxifen helped women with metastatic breast cancer live four months longer without their disease getting worse, according to a study presented Thursday at the San Antonio Breast Cancer Symposium.

Researchers randomly assigned 111 women to receive tamoxifen alone or tamoxifen plus Afinitor. Patients getting the combination lived a median of 8.6 months without disease progression, compared with 4.5 months for the tamoxifen-only group. After a median follow-up of around 22 months, nine patients in the combination arm had died compared with 25 deaths in the tamoxifen arm. All patients in this phase 2 trial had estrogen receptor–positive breast cancer that had previously been treated with an aromatase inhibitor, like Femara (letrozole) or Arimidex (anastrozole).

Afinitor—already approved for advanced kidney cancer—works by targeting mTOR, a protein that helps regulate the growth of cancer cells and blood vessels. Side effects associated with Afinitor include mouth ulcers, infections, cough and fatigue.

Three phase 3 studies, nicknamed BOLERO—short for Breast cancer trials of OraL EveROlimus— are now under way testing Afinitor in patients with locally advanced or metastatic breast cancer. one study will look at Afinitor in combination with the HER2-targeted drug Herceptin (trastuzumab) and the chemotherapy drug Taxol (paclitaxel). A second study will test the mTOR inhibitor in combination with Aromasin (exemestane), an aromatase inhibitor used to treat postmenopausal women with estrogen receptor–positive breast cancer. The third study will combine Afinitor with Herceptin and vinorelbine, a chemotherapy agent.

Talk about this article with other patients, caregivers, and advocates in the Breast CURE discussion group.
ADVERTISEMENT
Cure Connections
Related Articles
Living With Stage 4 Breast Cancer: My Semi-Charmed Kind of Life
I led a fairly charmed life up until about the age of 29. Life just always seemed to work out for me. I was the gal who had a flat tire 100 yards from the tire shop.
MRI Would Rather Not, Thank You
Male breast cancer survivor discusses a few uncertainties about his first MRI.
Healing in the Key of C: Joy in Music for Cancer Survivors
BY KHEVIN BARNES
The discord of our cancer is only a wrong note in our expression of the score of life. And I believe that, with due diligence and conscious camaraderie with our own bodies, we can live in harmony once more.
It Gets Better After the Shock of an Initial Cancer Diagnosis
A breast cancer and melanoma survivor testifies that her life got better again after hearing she had cancer.
Cancer Should Never Be a Usual Experience
I have a "usually" when it comes to cancer? How could anything ever be usual about cancer? Am I nuts?
Related Videos
Hope Rugo on Managing Sexual Dysfunction From Ovarian Suppression
BY HOPE S. RUGO
Hope S. Rugo discusses managing sexual dysfunction from ovarian suppression treatment for breast cancer.
Hope Rugo on Managing Effects From Ovarian Suppression in Patients With Breast Cancer
BY HOPE S. RUGO
Hope S. Rugo discusses managing effects from ovarian suppression treatment for breast cancer.
Kara Maxwell Explains Breast Cancer Clinical Trials
BY KARA MAXWELL
Kara Maxwell, instructor, medical oncologist, Basser Research Center for BRCA, University of Pennsylvania, explains how a breast cancer clinical trial works.
Kara Maxwell Provides Advice for a Patient With Early Stage Breast Cancer
BY KARA MAXWELL
Kara Maxwell, instructor, medical oncologist, Basser Research Center for BRCA, University of Pennsylvania, provides advice for a patient with early stage breast cancer.
Jennifer Klemp on Survivorship for Patients With Hereditary Breast Cancer
BY JENNIFER KLEMP, PHD, MPH
Jennifer Klemp, PhD, MPH, director, Breast Cancer Survivorship Center, The University of Kansas Cancer Center, discusses survivorship for patients with hereditary breast cancer.
$auto_registration$